Abstract:Cytochrome P450 3A4 (CYP3A4), a prominent member of the P450 enzyme superfamily, plays a crucial role in metabolizing various xenobiotics, including over 50% of clinically significant drugs. Evaluating CYP3A4 inhibition before drug approval is essential to avoiding potentially harmful pharmacokinetic drug-drug interactions (DDIs) and adverse drug reactions (ADRs). Despite the development of several CYP inhibitor prediction models, the primary approach for screening CYP inhibitors still relies on experimental methods. This might stem from the limitations of existing models, which only provide deterministic classification outcomes instead of precise inhibition intensity (e.g., IC50) and often suffer from inadequate prediction reliability. To address this challenge, we propose an uncertainty-guided regression model to accurately predict the IC50 values of anti-CYP3A4 activities. First, a comprehensive data set of CYP3A4 inhibitors was compiled, consisting of 27,045 compounds with classification labels, including 4395 compounds with explicit IC50 values. Second, by integrating the predictions of the classification model trained on a larger data set and introducing an evidential uncertainty method to rank prediction confidence, we obtained a high-precision and reliable regression model. Finally, we use the evidential uncertainty values as a trustworthy indicator to perform a virtual screening of an in-house compound set. The in vitro experiment results revealed that this new indicator significantly improved the hit ratio and reduced false positives among the top-ranked compounds. Specifically, among the top 20 compounds ranked with uncertainty, 15 compounds were identified as novel CYP3A4 inhibitors, and three of them exhibited activities less than 1 μM. In summary, our findings highlight the effectiveness of incorporating uncertainty in compound screening, providing a promising strategy for drug discovery and development.

Prediction of cytochrome P4502C9 inhibitors based on molecular indices

In Silico Prediction of CYP2C8 Inhibition with Machine-Learning Methods

Prediction of Cytochrome P450 Inhibition Using a Deep Learning Approach and Substructure Pattern Recognition

Classification of Cytochrome P450 Inhibitors and Noninhibitors Using Combined Classifiers.

Machine Learning Models to Predict Cytochrome P450 2B6 Inhibitors and Substrates

Harnessing machine learning to predict cytochrome P450 inhibition through molecular properties

Screening of cytochrome P450 3A4 inhibitors via in silico and in vitro approaches

The Computational Model to Predict Accurately Inhibitory Activity for Inhibitors Towardscyp3a4

Computational Prediction of the Isoform Specificity of Cytochrome P450 Substrates by an Improved Bayesian Method

Development of In Silico Models for Predicting Potential Time-Dependent Inhibitors of Cytochrome P450 3A4

Investigation of in silico studies for cytochrome P450 isoforms specificity

Evaluation of machine learning models for cytochrome P450 3A4, 2D6, and 2C9 inhibition

ADMET Evaluation in Drug Discovery. 19. Reliable Prediction of Human Cytochrome P450 Inhibition Using Artificial Intelligence Approaches

Machine learning to predict metabolic drug interactions related to cytochrome P450 isozymes

Application of Support Vector Machines to in Silico Prediction of Cytochrome P450 Enzyme Substrates and Inhibitors.

Prediction of human cytochrome P450 inhibition using a multi-task deep autoencoder neural network.

Novel Natural Inhibitors Of Cyp1a2 Identified By In Silico And In Vitro Screening

Classification models for predicting cytochrome p450 enzyme-substrate selectivity

Computational methods and tools to predict cytochrome P450 metabolism for drug discovery

An Uncertainty-Guided Deep Learning Method Facilitates Rapid Screening of CYP3A4 Inhibitors

Survey of Machine Learning Techniques for Prediction of the Isoform Specificity of Cytochrome P450 Substrates.